Cargando…
Evaluation of a Carbapenem-Saving Strategy Using Empirical Combination Regimen of Piperacillin-Tazobactam and Amikacin in Hemato-Oncology Patients
We implemented a carbapenem-saving strategy in hemato-oncology patients from 2013, using an empirical combination of piperacillin-tazobactam and amikacin for high-risk hemato-oncology patients with febrile neutropenia, who remain hemodynamically unstable > 72 hours despite initial cefepime treatm...
Autores principales: | Ko, Jae-Hoon, Kim, Si-Ho, Kang, Cheol-In, Cho, Sun Young, Lee, Nam Yong, Chung, Doo Ryeon, Peck, Kyong Ran, Song, Jae-Hoon |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327090/ https://www.ncbi.nlm.nih.gov/pubmed/30636947 http://dx.doi.org/10.3346/jkms.2019.34.e17 |
Ejemplares similares
-
212. Effectiveness of Empirical Piperacillin/tazobactam Compared to Cefepime for Bloodstream Infection Caused by Gram-Negative Bacilli
por: Ho Lee, Young, et al.
Publicado: (2023) -
2442. Outcomes in ESBL Bacteremia Empirically Treated With Piperacillin/Tazobactam or Carbapenems
por: John, Reeba, et al.
Publicado: (2018) -
Piperacillin–tazobactam as alternative to carbapenems for ICU patients
por: Pilmis, Benoit, et al.
Publicado: (2017) -
Empiric Piperacillin-Tazobactam versus Carbapenems in the Treatment of Bacteraemia Due to Extended-Spectrum Beta-Lactamase-Producing Enterobacteriaceae
por: Ng, Tat Ming, et al.
Publicado: (2016) -
Piperacillin/Tazobactam (ZOSYN)
por: Culver, Stephanie M., et al.
Publicado: (1996)